| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911236 | Lung Cancer | 2013 | 6 Pages |
Abstract
Erlotinib should be considered for first-line treatment in this subset of Japanese patients, with close monitoring for ILD-like events.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Koichi Goto, Makoto Nishio, Noboru Yamamoto, Kenichi Chikamori, Toyoaki Hida, Makoto Maemondo, Nobuyuki Katakami, Toshiyuki Kozuki, Hiroshige Yoshioka, Takashi Seto, Tamaki Fukuyama, Tomohide Tamura,